Effect of Teriparatide, Vibration and the Combination on Bone Mass and Bone Architecture in Chronic Spinal Cord Injury
Annual rept. 27 Sep 2013-26 Sep 2014
NORTHWESTERN UNIV EVANSTON IL
Pagination or Media Count:
Severe bone loss commonly occurs in individuals with chronic spinal cord injury who are nonweight-bearing and leads to an increased risk of lower extremity fractures. This 12 month, multi-site, double-blind, randomized, placebo-controlled study evaluates the efficacy and safety of two interventions known to be anabolic to bone, parathyroid hormone and mechanical loading provided as teriparatide and vibration, respectively in 60 SCI individuals with low bone mass. At the end of the fourth year of this project, enrollment has been completed. 56 out of 60 participants completed year 1 of the study retention rate of 93 25 participants who completed elected to begin a one year open-label extension of teriparatide therapy. No safety issues have arisen during the course of the study. Data from the first year of study are being finalized, and results regarding efficacy will only be available after database lock and subsequent analysis.
- Medicine and Medical Research